NASDAQ:FONR

FONAR Competitors

$17.62
-0.29 (-1.62 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.53
Now: $17.62
$18.05
50-Day Range
$17.79
MA: $18.87
$20.35
52-Week Range
$16.59
Now: $17.62
$26.49
Volume25,883 shs
Average Volume35,471 shs
Market Capitalization$115.48 million
P/E Ratio16.62
Dividend YieldN/A
Beta1.07

Competitors

FONAR (NASDAQ:FONR) Vs. EDAP, EYES, IRIX, BSGM, NDRA, and SLNO

Should you be buying FONR stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to FONAR, including Edap Tms (EDAP), Second Sight Medical Products (EYES), IRIDEX (IRIX), BioSig Technologies (BSGM), ENDRA Life Sciences (NDRA), and Soleno Therapeutics (SLNO).

Edap Tms (NASDAQ:EDAP) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Edap Tms and FONAR's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edap Tms$50.23 million4.84$1.69 million$0.06138.83
FONAR$85.69 million1.35$8.24 millionN/AN/A

FONAR has higher revenue and earnings than Edap Tms.

Institutional and Insider Ownership

62.1% of FONAR shares are owned by institutional investors. 8.6% of FONAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Profitability

This table compares Edap Tms and FONAR's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edap Tms-4.03%-11.54%-5.78%
FONAR8.28%5.57%3.99%

Analyst Ratings

This is a breakdown of recent ratings for Edap Tms and FONAR, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edap Tms00303.00
FONAR0000N/A

Edap Tms currently has a consensus price target of $12.50, suggesting a potential upside of 50.06%. Given Edap Tms' higher possible upside, research analysts plainly believe Edap Tms is more favorable than FONAR.

Summary

FONAR beats Edap Tms on 8 of the 12 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Second Sight Medical Products and FONAR, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
FONAR0000N/A

Profitability

This table compares Second Sight Medical Products and FONAR's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
FONAR8.28%5.57%3.99%

Institutional & Insider Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Second Sight Medical Products and FONAR's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million60.60$-33,590,000.00($1.91)-3.84
FONAR$85.69 million1.35$8.24 millionN/AN/A

FONAR has higher revenue and earnings than Second Sight Medical Products.

Volatility & Risk

Second Sight Medical Products has a beta of 2.49, suggesting that its share price is 149% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Summary

FONAR beats Second Sight Medical Products on 7 of the 10 factors compared between the two stocks.

FONAR (NASDAQ:FONR) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares FONAR and IRIDEX's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FONAR$85.69 million1.35$8.24 millionN/AN/A
IRIDEX$43.45 million2.53$-8,810,000.00($0.64)-11.05

FONAR has higher revenue and earnings than IRIDEX.

Insider and Institutional Ownership

62.1% of FONAR shares are held by institutional investors. Comparatively, 32.6% of IRIDEX shares are held by institutional investors. 8.6% of FONAR shares are held by insiders. Comparatively, 2.0% of IRIDEX shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares FONAR and IRIDEX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FONAR8.28%5.57%3.99%
IRIDEX-21.54%-38.60%-24.99%

Volatility & Risk

FONAR has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for FONAR and IRIDEX, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FONAR0000N/A
IRIDEX00203.00

IRIDEX has a consensus price target of $6.50, indicating a potential downside of 8.06%. Given IRIDEX's higher probable upside, analysts plainly believe IRIDEX is more favorable than FONAR.

Summary

FONAR beats IRIDEX on 8 of the 12 factors compared between the two stocks.

FONAR (NASDAQ:FONR) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares FONAR and BioSig Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FONAR$85.69 million1.35$8.24 millionN/AN/A
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A

FONAR has higher revenue and earnings than BioSig Technologies.

Insider and Institutional Ownership

62.1% of FONAR shares are held by institutional investors. Comparatively, 18.3% of BioSig Technologies shares are held by institutional investors. 8.6% of FONAR shares are held by insiders. Comparatively, 19.5% of BioSig Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares FONAR and BioSig Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FONAR8.28%5.57%3.99%
BioSig TechnologiesN/A-244.64%-213.88%

Volatility & Risk

FONAR has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for FONAR and BioSig Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FONAR0000N/A
BioSig Technologies0000N/A

Summary

FONAR beats BioSig Technologies on 6 of the 8 factors compared between the two stocks.

ENDRA Life Sciences (NASDAQ:NDRA) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and target prices for ENDRA Life Sciences and FONAR, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ENDRA Life Sciences0000N/A
FONAR0000N/A

Profitability

This table compares ENDRA Life Sciences and FONAR's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ENDRA Life SciencesN/A-492.76%-288.58%
FONAR8.28%5.57%3.99%

Insider and Institutional Ownership

2.8% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 9.6% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares ENDRA Life Sciences and FONAR's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life Sciences$10,000.009,152.00$-13,310,000.00($2.34)-0.94
FONAR$85.69 million1.35$8.24 millionN/AN/A

FONAR has higher revenue and earnings than ENDRA Life Sciences.

Risk & Volatility

ENDRA Life Sciences has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Summary

FONAR beats ENDRA Life Sciences on 7 of the 10 factors compared between the two stocks.

FONAR (NASDAQ:FONR) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for FONAR and Soleno Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FONAR0000N/A
Soleno Therapeutics00303.00

Soleno Therapeutics has a consensus target price of $8.6667, indicating a potential upside of 687.88%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than FONAR.

Profitability

This table compares FONAR and Soleno Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FONAR8.28%5.57%3.99%
Soleno TherapeuticsN/A-88.69%-51.63%

Insider & Institutional Ownership

62.1% of FONAR shares are owned by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are owned by institutional investors. 8.6% of FONAR shares are owned by company insiders. Comparatively, 74.9% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares FONAR and Soleno Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FONAR$85.69 million1.35$8.24 millionN/AN/A
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.57

FONAR has higher revenue and earnings than Soleno Therapeutics.

Volatility & Risk

FONAR has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Summary

FONAR beats Soleno Therapeutics on 8 of the 11 factors compared between the two stocks.


FONAR Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Edap Tms logo
EDAP
Edap Tms
1.3$8.33-2.2%$242.94 million$50.23 million-138.83Increase in Short Interest
Gap Down
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.34-4.9%$204.85 million$3.38 million-3.84Decrease in Short Interest
IRIDEX logo
IRIX
IRIDEX
0.9$7.07-5.0%$109.73 million$43.45 million-12.85
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.43-3.8%$109.04 millionN/A0.00
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.20-4.1%$91.52 million$10,000.00-1.20
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.10-7.3%$87.70 millionN/A-1.45Analyst Downgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.74-6.3%$84.35 million$2.39 million-2.20Gap Down
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$17.10-1.2%$39.52 million$1.50 million-0.98
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.03-5.4%$30.37 million$5.51 million-0.10News Coverage
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63-2.7%$27.20 million$6.57 million-0.01
Star Equity logo
STRR
Star Equity
0.1$2.76-3.6%$13.59 million$114.18 million-0.88
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.